^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

622 PD-L1 is a potential predictive biomarker for response to RM-1929 treatment in recurrent head and neck squamous cell carcinoma patients

Published date:
11/09/2020
Excerpt:
PD-L1 expression prior to RM-1929 treatment was assessed by immunohistochemistry in 18 out of 30 patients enrolled...These results suggest that rHNSCC patients with lower PD-L1 expression levels may be more responsive to RM-1929 treatment…
DOI:
http://dx.doi.org/10.1136/jitc-2020-SITC2020.0622
Trial ID: